Naomi Iwata

Naomi Iwata

Auto-generated profile, based on publicly available information

Naomi Iwata

Department of Infection and Immunology, Aichi Children's Health and Medical Center, Aichi, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2020 in Intestinal Research
Verified
Journal Article
Open access
PDF file
KAKatsuhiro Arai
Katsuhiro Arai
RKReiko Kunisaki 
Reiko Kunisaki 
FKFumihiko Kakuta
Fumihiko Kakuta
SHShin-Ichiro Hagiwara
Shin-Ichiro Hagiwara
TMTakatsugu Murakoshi
Takatsugu Murakoshi
TFTakeo Fujiwara
Takeo Fujiwara
Background/Aims: There are few published registry studies from Asia on pediatric inflammatory bowel disease (IBD). Registry network data enable comparisons among ethnic groups. This study examined the characteristics of IBD in Japanese children and compared them with those in European children.Methods: This was a cross-sectional multicenter registry study of newly diagnosed Japanese pediatric IBD patients. The Paris classification was used to categorize IBD features, and results were compared with published EUROKIDS data.Results: A total of 265 pediatric IBD patients were initially registered, with 22 later excluded for having incomplete demographic data. For the analysis, 91 Crohn’s disease (CD), 146 ulcerative colitis (UC), and 6 IBD-unclassified cases were eligible. For age at diagnosis, 20.9% of CD, 21.9% of UC, and 83.3% of IBD-unclassified cases were diagnosed before age 10 years. For CD location, 18.7%, 13.2%, 64.8%, 47.3%, and 20.9% were classified as involving L1 (ileocecum), L2 (colon), L3 (ileocolon), L4a (esophagus/stomach/duodenum), and L4b (jejunum/proximal ileum), respectively. For UC extent, 76% were classified as E4 (pancolitis). For CD behavior, B1 (non-stricturing/non-penetrating), B2 (stricturing), B3 (penetrating), and B2B3 were seen in 83.5%, 11.0%, 3.3%, and 2.2%, respectively. A comparison between Japanese and European children showed less L2 involvement (13.2% vs. 27.3%, P< 0.01) but more L4a (47.3% vs. 29.6%, P< 0.01) and L3 (64.8% vs. 52.7%, P< 0.05) involvement in Japanese CD children. Pediatric perianal CD was more prevalent in Japanese children (34.1% vs. 9.7%, P< 0.01).Conclusions: Upper gastrointestinal and perianal CD lesions are more common in Japanese children than in European children.

3 September 2018 in Modern Rheumatology
Verified
Journal Article
Closed access
NINaomi Iwata
Naomi Iwata
HNHaruna Nakaseko
Haruna Nakaseko
TKToaki Kohagura
Toaki Kohagura
RYRyuhei Yasuoka
Ryuhei Yasuoka
NANaoki Abe
Naoki Abe
YMYoshinao Muro
Yoshinao Muro
Objectives: This study investigated the association between myositis-specific autoantibodies (MSAs) and clinical subsets of juvenile dermatomyositis (JDM) in Japanese patients. Methods: Twenty-one patients at a single center who developed initial or relapsed JDM from 2011 to 2016 were analyzed. Serum concentrations of MSAs against TIF1-γ, MDA5, NXP2, Mi-2, ARS, and SAE were measured by enzyme-linked immunosorbent assays. Clinical symptoms and laboratory data were obtained from clinical records. Clinical characteristics were compared in patients with autoantibodies against TIF1-γ, MDA5, and NXP2. Results: Of the 21 patients, 20 (95.2%) were positive for one or more MSAs, including nine (42.9%), five (23.8%), six (28.6%), and one (4.8%) positive for anti-TIF1-γ, anti-MDA5, anti-NXP2, and anti-Mi-2 autoantibodies. No patient was positive for anti-ARS or anti-SAE autoantibodies. The frequency of diffuse cutaneous lesions was higher in patients with anti-TIF1-γ autoantibodies. Anti-MDA5 autoantibody-positive patients had features of interstitial lung disease on chest computed tomography. Severe muscle damage at disease onset was significantly associated with positivity for anti-NXP2 autoantibodies. Conclusion: Similar to findings in Western countries, the clinical characteristics of JDM in Japanese may differ for each type of MSAs.

15 September 2020 in Modern Rheumatology
Verified
Journal Article
Closed access
MTMinako Tomiita
Minako Tomiita
IKIchiro Kobayashi
Ichiro Kobayashi
YIYasuhiko Itoh
Yasuhiko Itoh
YIYuzaburo Inoue
Yuzaburo Inoue
NINaomi Iwata
Naomi Iwata
Masaaki MoriMasaaki Mori
Masaaki Mori
There are a considerable number of pediatric patients with Sjögren’s syndrome (SS), however, SS is generally considered rare among children. Pediatric patients with SS report fewer sicca symptoms; therefore, many are under-diagnosed and cannot access appropriate medical management. Therefore, we propose a newly developed guidance for the diagnosis, treatment and management of pediatric SS, including epidemiology, clinical features, and diagnostic examination methodology. The aim of this guidance is to standardize the medical care of pediatric SS in Japan and we published the Japanese version by YODOSHA in 2018. This article is the English version, which is summarized and updated. This guidance will need to be revised in the near future as additional clinical data becomes available.

7 March 2024 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
TMTakayuki Miyamoto
Takayuki Miyamoto
KIKazushi Izawa
Kazushi Izawa
SMSho Masui
Sho Masui
AYAtsue Yamazaki
Atsue Yamazaki
YYYuichi Yamasaki
Yuichi Yamasaki
TGthe Japan CAPS Working Group
the Japan CAPS Working Group

21 October 2022 in Modern Rheumatology
Verified
Journal Article
Open access
PDF file
NINaomi Iwata
Naomi Iwata
KNKenichi Nishimura
Kenichi Nishimura
RHRyoki Hara
Ryoki Hara
TITomoyuki Imagawa
Tomoyuki Imagawa
MSMasaki Shimizu
Masaki Shimizu
SYShumpei Yokota
Shumpei Yokota
Objectives: The objective of the study was to report the efficacy and safety of canakinumab treatment in Japanese patients with systemic juvenile idiopathic arthritis (sJIA) over a 48-week study period. Methods: Patients were administered canakinumab 4 mg/kg (maximum dose 300 mg) every 4 weeks, with no dose adjustments. The key outcome measures included adapted American College of Rheumatology paediatric (aACR pedi) 30/50/70/90/100 response, proportion of patients with inactive disease, and corticosteroid (CS) tapering. Results: In total, 16/19 (84.2%) patients received canakinumab for ≥96 weeks reaching end-of-study (EOS) visit without premature discontinuation. Regardless of the level of joint involvement at baseline, high aACR pedi responses were observed throughout the study; at the EOS, aACR pedi 90/100 response rates were 84.2%/63.2%, respectively. The proportion of patients who successfully tapered CSs at EOS was 66.7% (12/18), of which 10 patients were steroid-free. The most common adverse events were infections (238.3 events/100 patient-years). Serious adverse events were observed in 52.6%. The event (n=1) adjudicated as possible macrophage activation syndrome was preceded by sJIA flare. No deaths were reported. Conclusions: Canakinumab treatment resulted in a sustained treatment response in sJIA patients over 48 weeks and was associated with CS tapering in majority of patients. No new safety findings were reported.

17 September 2020 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
NINaomi Iwata
Naomi Iwata
MTMinako Tomiita
Minako Tomiita
IKIchiro Kobayashi
Ichiro Kobayashi
YIYusaburo Inoue
Yusaburo Inoue
YNYukiko Nonaka
Yukiko Nonaka
MMMasaaki Mori
Masaaki Mori
Background: The European League Against Rheumatism (EULAR) Sjögren Syndrome Disease Activity Index (ESSDAI) has been utilized to assess Sjögren syndrome-related systemic involvement in adult patients. To date, however, the ESSDAI has not been validated in children with primary Sjögren’s syndrome. This study evaluated the applicability of the ESSDAI to Japanese children with primary Sjögren’s syndrome. Methods: The medical records of children who had been diagnosed with Sjogren syndrome at age ≤ 16 years between June 2011 and October 2016 were collected, and their ESSDAIs at initial presentation were calculated. Clinical symptoms and treatment regimens were surveyed by questionnaire, and patients were divided into groups based on ESSDAI and glucocorticoid dosages. The associations of ESSDAI scores with treatment regimens were analyzed statistically. Results: The study subjects included 31 children (3 boys, 28 girls) with primary Sjögren’s syndrome. Their median age at disease onset was 10 years (interquartile range [IQR], 8–13 years), and their median initial ESSDAI was 7.0 (IQR; 5.0–15.0). ESSDAI-determined disease activity was high in nine patients (29.0%), moderate in 15 (48.4%), and low in seven (22.6%). During the first year after their initial visit, 14 patients (45.2%) were treated with prednisolone (PSL) and six (19.4%) with immunosuppressants. Dose of PSL was significantly associated with ESSDAI score. Median ESSDAI score was significantly higher in patients treated with high/medium- than with no/low-dose PSL (16.5 [IQR 10.5–18.0] vs 5.0 [IQR 3.0–8.5]). Eight (66.7%) of 12 patients administered medium/high-dose PSL and one (5.3%) of 19 administered no/low-dose PSL had high disease activity on ESSDAI. Conclusion: Disease activity assessed by ESSDAI tended to be consistent with disease activity assessed by pediatric rheumatologists in determining treatment regimens. ESSDAI is useful for assessing disease activity in Japanese children with primary Sjögren’s syndrome.